Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
You wouldn't use uncalibrated equipment or contaminated reagents, would you
215 Despite these pharmacological benefits, low oral bioavailability remains a major limitation for clinical application
Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients
Current international guidelines emphasize individualized glycemic targets while minimizing hypoglycemia risk and weight gain when selecting antidiabetic therapies [1]
Redza-Dutordoir M, Averill-Bates DA
US$ 21.42
US$ 26.89
US$ 20.94
